News >

Apalutamide Maintains Health-Related QoL in Nonmetastatic CRPC

Brandon Scalea
Published: Monday, Sep 17, 2018

Fred Saad, MD

Fred Saad, MD

Treatment with apalutamide (Erleada) was not associated with a significant impact on health-related quality of life (HRQoL) in patients with high-risk nonmetastatic castration-resistant prostate cancer, according to patient-reported outcome (PRO) data from the phase III SPARTAN trial.

, Saad, professor and chief, Urology, director of Genitourinary Oncology, University of Montreal Hospital Centers, discussed the clinical significance of the SPARTAN trial, the HRQoL data, and remaining steps in the treatment of patients with nonmetastatic CRPC.

OncLive: Please provide some background to the SPARTAN trial.

Saad: SPARTAN was one of the first clinical trials done in patients with nonmetastatic CRPC using an extremely effective class of agents that we use in metastatic disease. Apalutamide is a new-generation androgen receptor (AR) inhibitor that was tested in patients with high-risk CRPC. We defined high risk by prostate-specific antigen (PSA) doublet time. This is the best predictor of how quickly patients will become metastatic and likely die from their disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x